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Abstract
An Extramedullary Plasmacytoma (EMP) is characterized by a neoplastic proliferation of clonal plasma cells outside the medullary
cavity. EMPs are a rare occurrence compared to other malignant plasma cell disorders and account for approximately 3-5% of
plasma-cell neoplasms. Although most cases of EMP are not immediately life threatening at diagnosis, EMPs can progress to
Multiple Myeloma (MM) and thus, warrant monitoring. Currently, there are no standard guidelines for when and how to monitor
patients who are diagnosed with or treated for a solitary plasmacytoma. We present a case of solitary EMP who was treated
adequately and definitively but developed a distinct, non-contiguous subsequent solitary EMP and was only discovered due to
surveillance 18F-Fludeoxyglucose Positron Emission Tomography (18F-FDG) (PET) scan. Uniform surveillance guidelines should be
developed and the potential benefits of PET and other imaging techniques as well as their cost should be considered.
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CASE REPORT
A 37-year-old female presented with significant nausea, vomiting,
and abdominal pain for two weeks. On examination there were
no localizing symptoms, with normal bowel sounds, diffuse mild
abdominal tenderness and no organomegaly or ascites. Computed
Tomographic (CT) imaging showed that she had a 5.1 cm x 4.1 cm
lesion involving the second part of duodenum and the pancreatic
head [Table/Fig-1]. An upper gastrointestinal endoscopy and biopsy
from the lesion showed this mass was infiltrated by plasma cell
[Table/Fig-2a] showing lambda-restriction [Table/Fig-2b] and were
also positive for CD138 and MUM-1, while negative for kappa light
chains, leading to the diagnosis of EMP. A skeletal survey did not
show any abnormalities, and no clonal plasma cells were detected
in the bone marrow on a core biopsy. The results of the patient’s
laboratory tests were normal [Table/Fig-3]. Thus, the diagnosis of a
solitary EMP was made. The patient underwent definitive involvedsite radiation therapy with 45 Gy administered over a four-week
period. Results from a follow up 18F-FDG PET and CT scan were
normal [Table/Fig-4]. Due to persistent symptoms from adhesions,
which were considered a sequela of radiation therapy, the patient
underwent a subsequent whipple procedure, which resolved the
symptoms. A follow up surveillance PET/CT scan was conducted
three months later and was reported normal. On further routine
surveillance PET/CT, approximately seven months after the primary

[Table/Fig-1]: CT scan showing a duodenal mass on coronal and axial sections.
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treatment, the patient was found to have an FDG-avid, asymptomatic,
left-sided adnexal mass with a maximum Standardized-Uptake
Value (SUV max) of 8.7 [Table/Fig-5]. Considering the previous
diagnosis of solitary EMP, the possibility of another EMP was
entertained. She underwent surgical excision of the mass to confirm

[Table/Fig-2]: (a) Plasmacytosis in excisional biopsy specimen of duodenal/pancreatic head mass (40X) at the time of initial solitary extramedullary plasmacytoma (EMP);
(b) Lambda restriction in plasma cells from excisional biopsy specimen of duodenal/
pancreatic head mass (40X).

At the
Time of GI
Plasmacytoma

After Resolution
of GI
Plasmacytoma

At the Time
of Ovarian
Plasmacytoma

12.1 g/dL

12.7 g/dL

10.6 g/dL

Total leucocyte count

10.1 X10 /L

3.1 X10 /L

5.2 X109/L

Platelet count

468 X109/L

313 X109/L

442 X109/L

Calcium

9.8 mg/dL

9.5 mg/dL

9.2 mg/dL

Albumin

4.6 g/dL

4.6 g/dL

4.7 g/dL

Creatinine

0.6 mg/dL

0.6 mg/dL

0.6 mg/dL

Kappa light chains

13.2 mg/L

14.3 mg/L

13.4 mg/L

Lambda light chains

12.1 mg/L

17.9 mg/L

15.8 mg/L

Kappa/lambda ratio

1.09

0.79

0.85

Serum protein
electrophoresis

Normal

Normal

Normal

Skeletal survey

Normal

Normal

Normal

Hemoglobin

9

9

[Table/Fig-3]: Timeline of selected laboratory parameters at the time of diagnosis
and follow up.
GI = gastrointestinal
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[Table/Fig-5]: 18F-FDG PET/CT scan showing a hypermetabolic soft tissue leftsided adnexal mass.

[Table/Fig-4]: Post-treatment18 F-FDG PET/CT scan showing resolution of hypermetabolic lesion (coronal section).

a diagnosis, and a histopathological evaluation confirmed it to be
a plasmacytoma [Table/Fig-6]. The plasma cells were again noted
to be lambda-restricted, similar to the original plasmacytoma. A
repeat bone marrow biopsy and laboratory testing did not show
any other abnormalities suggesting an underlying active or evolving
MM. She had mild anemia, but this was microcytic, and on further
workup her anemia was consistent with iron deficiency [Table/Fig-3].
Due to lack of data on the benefit of adjuvant radiation therapy in
plasmacytomas having undergone definitive surgical treatment, it
was not considered. She was recommended to initiate systemic
therapy after the second EMP occurrence to prevent further EMP or
progression to active MM but she opted against it and was followed
with active surveillance. The patient received PET/CT scans every
three months for the first year and then every six months thereafter.
She remains free of any plasmacytoma recurrence or progression to
MM three years after the second episode.

DISCUSSION
EMPs are a rare occurrence compared to other malignant plasma
cell disorders and account for approximately 3-5% of plasmacell neoplasms [1]. The most common sites of EMP involvement
are respiratory and gastrointestinal systems [2,3]. Although most
cases of EMP are not immediately life threatening at diagnosis,
EMPs can progress to MM and thus, warrant monitoring. Previous
studies have reported that less than 7% patients with solitary bone
plasmacytomas will develop a local recurrence after tumouricidal
radiation [4] and approximately 10-15% of patients will ultimately
develop MM with a higher (20%) progression rate in those with
minimal bone marrow involvement [4,5]. Of note, less data is
available regarding EMP that is not bone-based.
In recent years, the survival of patients with MM has significantly
improved [6]. This is likely due to the availability of increasingly effective
therapeutic agents that are well tolerated over long durations of
treatment. Because of these encouraging improvements in patient
outcomes and the availability of highly effective therapeutic agents,
2

[Table/Fig-6]: Plasmacytosis in excisional biopsy of ovarian mass (40X) at the time
of recurrent EMP.

the International Myeloma Working Group (IMWG) has revised the
definition of MM with an aim of preventing end-organ damage
by initiating systemic treatment before such damage occurs [5].
The workup and definition of a solitary plasmacytoma as well as
its risk of progression to MM has been well defined, and PET/CT
scans have emerged as an important modality that helps confirm
diagnoses and leads to definitive therapy in at least some cases
[5]. Another imaging modality that is recommended frequently to
confirm the solitary nature of an EMP is a Magnetic Resonance
Imaging (MRI) of the spine and pelvis [7], but this is typically more
expensive than a PET/CT scan and takes a longer duration to
complete. Furthermore, while a MRI may be beneficial in detecting
solitary plasmacytomas of bony origin, MRIs confined to certain
body parts may miss EMP not associated with a bony lesion. The
IMWG published a consensus statement regarding the use of MRI
in the management of patients with MM [8]. The whole-body MRI is
the recommended MR modality and its substitution by just the axial
MRI can result in a significantly decreased sensitivity in recognizing
lesions [9]. On the other hand a PET/CT scan can provide a faster,
whole-body modality with a sensitivity of 96%, specificity of 77%
and a particular advantage of detecting extramedullary disease
[10]. In a meta-analysis highlighting the comparison of MRI and
PET/CT, the major advantages of MRI were a higher sensitivity for
detecting diffuse marrow infiltration and localized vertebral disease
with increased risk of fracture, while the PET/CT detected a higher
number of osteolytic lesions [11].
Despite the guidelines for diagnosis of an EMP, there are no specific
published guidelines on how to perform surveillance in patients with
plasmacytomas, especially using PET/CT scans [12]. The current
NCCN guidelines for MM recommend that follow up imaging be
used in cases of solitary plasmacytomas only if clarification is
required for changes on the imaging studies noted at baseline or if
Journal of Clinical and Diagnostic Research. 2017 Apr, Vol-11(4): XD01-XD03
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there is suspicion of disease progression in the form of new onset
bone pain or positive laboratory test results [12]. This strategy, while
a prudent utilization of available resources, does not conform to the
essence of recent trends in MM, where the goal has been to detect
disease presence before it causes end organ damage [5]. In our
patient, while the PET/CT scan was able to detect the EMPs on
both occasions, the patient had no symptoms and was otherwise
healthy at the time of the second occurrence.
PET/CT scans are currently considered a standard of care diagnostic
modality for MM and plasmacytomas by most insurance carriers as
well as the Centers for Medicare and Medicaid Services (CMS) in
the United States (US) [5]. While the exact out-of-pocket cost for
a PET/CT scan to a patient may vary significantly across the US,
several databases quote a wide range of costs for the technique
($1,500-$13,000) based on the insurance coverage, geographic
location, etc., [13]. Considering the reported utility of PET/CT scans
for monitoring MM [14] and the lack of data for similar benefits for
plasmacytomas, this is an area that requires standardized guidelines,
especially with a cost-benefit view.

CONCLUSION
The present case highlights the importance of imaging by PET/
CT scans for patients with solitary plasmacytomas, and more
importantly, it reflects the utility that this imaging modality can
have for patient follow up and surveillance. While a PET/CT scan is
almost universally performed to confirm the diagnosis of a solitary
plasmacytoma, standardized guidelines need to be developed to
use this and possibly other technique for patient surveillance.
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